Skip to main content
. 2023 Mar 4;16:28. doi: 10.1186/s13104-023-06291-5

Table 2.

Pre- and post-intervention values of parameters and their comparison between the two groups

Parameters Time Group P value Mean difference*
(95% CI)
Drug Placebo
Pain severity

Baseline (week 0)

End (week 4)

P-value

16 [13–18]

4 [2–7.5]

 < 0.001c

15 [10–19]

8 [4–17.5]

 < 0.001c

0.958a

0.001b

3.91 ± 1.44 (1.02–6.80)
Flexibility

Baseline (week 0)

End (week 4)

P-value

6 [4–7]

2 [0–2]

 < 0.001c

6 [4–8]

4 [1.5–6]

< 0.001c

0.356a

0.001b

1.84 ± 0.50 (0.83–2.85)
Function

Baseline (week 0)

End (week 4)

P-value

46.54 ± 11.24

22.30 ± 15.48

 < 0.001d

47.68 ± 11.55

36.00 ± 18.40

< 0.001d

0.68b

 < 0.001b

13.70 ± 4.09 (5.53–21.86)
Total score of WOMAC

Baseline (week 0)

End (week 4)

P-value

67 [58–79]

24 [15–36.5]

 < 0.001c

70 [54–83.5]

52 [25–74]

< 0.001c

0.646a

0.001b

19.08 ± 5.71 (7.67–30.48)
VAS score

Baseline (week 0)

End (week 4)

P-value

9 [7–10]

4 [2.5–5]

 < 0.001c

9 [8–9.5]

6 [3.5–9]

< 0.001c

0.804a

0.001b

1.92 ± 0.62 (0.67–3.16)
PGA score

Baseline (week 0)

End (week 4)

P-value

3 [2.5–4]

1.8 [1–2.5]

 < 0.001c

3.5 [3, 4]

3 [1.9–3.5]

< 0.001c

0.918a

0.001b

0.78 ± 0.26 (0.26–1.30)

WOMAC Western Ontario and McMaster Universities Osteoarthritis Index, VAS visual analogue scale, PGA patient global assessment

aMann-Whithney U test

bANCOVA test

cWilcoxon Signed Rank test

dPaired Sample T-test

*Mean ± SE of difference for end values according to ANCOVA test